Physician profile
Catherine Paszek
NPI 1689038200
$1,353.53
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $493 · 2021: $479 · 2022: $141 · 2023: $65.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $367.69 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $207.57 | 2019-2022 | |
| Cranial Technologies, INC | $158.87 | 2019-2023 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $120.67 | 2020-2022 | |
| Kaleo, INC. | $115.51 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $47.11 | 2019-2020 | |
| Genentech USA, INC. | $45.56 | 2020-2021 | |
| Sobi, INC | $42.62 | 2020 | |
| Adlon Therapeutics L.P. | $42.57 | 2019-2020 | |
| Abbvie INC. | $42.36 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $36.98 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $35.03 | 2019-2020 | |
| Phadia US INC. | $32.42 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $25.17 | 2023 | Jornay Pm |
| Neos Therapeutics, Lp | $16.93 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhodes Pharmaceuticals L.P. | $16.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Paszek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.